In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Velo for adults with relapsed or refractory follicular lymphoma, and Alnylam announces a $250 million investment in a new Massachusetts manufacturing facility.

Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

<div>The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. </div>

Science

Life Sciences

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com" rel="noopener noreferrer">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.&nbsp;

Share Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

Sign up to save your podcasts

Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

More shows like Pharmaceutical Executive

Planet Money

Economist Podcasts

Motley Fool Money

WSJ Your Money Briefing

WSJ What’s News

Bloomberg Businessweek

WSJ Tech News Briefing

HBR IdeaCast

Bold Names

The Indicator from Planet Money

The Readout Loud

Thoughts on the Market

The Journal.

Bloomberg Daybreak: US Edition

WSJ's Take On the Week